Please try another search
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum TKa, a biomarker assay that measures thymidine kinase activity, which reflects tumor cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Anders Rylander | 52 | 2010 | CEO & Director |
Lars Erik Holmqvist | 63 | 2018 | Independent Chairman of the Board |
Maria Birgitte Holmlund | 66 | 2016 | Independent Director |
Jarl Ulf Jungnelius | 72 | 2014 | Independent Director |
Jesper Soderqvist | 57 | 2013 | Independent Director |
Annika Carlsson Berg | 60 | 2020 | Independent Director |
Marie-Louise Fjallskog | 59 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review